Equillium, Inc. promoted Maple Fung, M.D., from SVP of Clinical Development to the position of Chief Medical Officer, where she will oversee Equillium's clinical development programs and the ongoing integration of the Company's development and translational research efforts to advance programs through all phases of clinical development.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.65 USD | -3.51% | +0.01% | +128.23% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+128.23% | 60.29M | |
+25.61% | 661B | |
+26.74% | 566B | |
-6.64% | 352B | |
+19.42% | 332B | |
+3.49% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.54% | 145B |
- Stock Market
- Equities
- EQ Stock
- News Equillium, Inc.
- Equillium, Inc. Promotes Maple Fung to the Position of Chief Medical Officer